1. Ireland Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Iterum Therapeutics plc

Iterum Therapeutics plc

ITRM
Iterum Therapeutics plcUS flagNASDAQ Capital Market
0.03
USD
+0.00
- -
1.60MMarket Cap

Total Valuation

Iterum Therapeutics plc carries a market capitalization of 1.60M, placing it among publicly traded companies globally. Its enterprise value stands at 47.27M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap1.60M
Enterprise Value47.27M

Share Statistics

Iterum Therapeutics plc currently has 48.99M shares outstanding.

Shares Outstanding48.99M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 62.91, and the price-to-book ratio stands at -0.05.

PE RatioN/A
PS Ratio62.91
PB Ratio-0.05
P/TBV Ratio-0.94
P/FCF Ratio-1.26
P/OCF Ratio-1.26

Enterprise Valuation

EV / Sales121.20
EV / EBITDAN/A
EV / EBITN/A
EV / FCFN/A

Financial Position

Iterum Therapeutics plc maintains a current ratio of 2.13, meaning it holds 2.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -457.05, indicating conservative leverage, while an interest coverage ratio of -8.93 demonstrates limited ability to service its debt obligations.

Current Ratio2.13
Quick Ratio1.80
Debt / Equity-457.05
Debt / EBITDA-1.75
Interest Coverage-8.93

Financial Efficiency

Return on Equity (ROE)N/A
Return on Assets (ROA)-111.35
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover1.23

Taxes

Income Tax276,000.00
Effective Tax RateN/A

Stock Price Statistics

Iterum Therapeutics plc's stock has declined approximately -97.32143% over the past 52 weeks. The 50-day moving average sits at 0.21, while the 200-day moving average is 0.52.

Beta (5Y)N/A
52-Week Price Change-97.32143%
50-Day Moving Average0.21
200-Day Moving Average0.52
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Iterum Therapeutics plc generated 390,000.00 in revenue and converted that into -26.96M in net income, yielding earnings per share of -0.74. EBITDA reached -19.32M, while operating income came in at -20.64M.

Revenue390,000.00
Gross Profit-317,000.00
Operating Income-20.64M
Pretax Income-26.68M
Net Income-26.96M
EBITDA-19.32M
EBIT-20.64M
Earnings Per Share (EPS)-0.74

Balance Sheet

Iterum Therapeutics plc holds 11.00M in cash and equivalents against 33.74M in total debt, resulting in a net debt position of 22.73M. Total book value stands at -505.96M, with working capital of 7.30M providing operational flexibility.

Cash & Cash Equivalents11.00M
Total Debt33.74M
Net Debt22.73M
Equity (Book Value)-505.96M
Book Value Per Share-13.82
Working Capital7.30M

Cash Flow

Iterum Therapeutics plc produced -19.51M in operating cash flow over the past twelve months. After subtracting -14,000.00 in capital expenditures, free cash flow totaled -19.53M - equivalent to -0.53 per share.

Operating Cash Flow-19.51M
Capital Expenditures-14,000.00
Free Cash Flow-19.53M
FCF Per Share-0.53

Margins

Iterum Therapeutics plc operates with a gross margin of -81.28, reflecting its pricing power and cost economics. The operating margin of -5,292.31 and net profit margin of -6,913.08 provide insight into operational efficiency.

Gross Margin-81.28
Operating Margin-5,292.31
Pretax Margin-6,842.31
Profit Margin-6,913.08
EBITDA Margin-4,954.87

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield-65.38
FCF Yield-79.47

Stock Splits

Iterum Therapeutics plc's most recent stock split took place on August 18, 2022 with a 15:1 split ratio.

Last Split Date8/18/2022
Split Ratio15:1

Scores

Iterum Therapeutics plc posts an Altman Z-Score of -55.31, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-55.31